SIRT1 transgenic mice, which show reduced PPARγ acetylation, are protected from ethanol-induced hepatic steatosis, suggesting that modulating PPARγ acetylation through SIRT1 could be an effective therapeutic strategy (Yu et al., 2016b). This evidence concerns the gene PPARG and fatty liver disease.